Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

JRCT ID: jRCT2061230009

Registered date:29/04/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Triple Negative Breast Neoplasms
• Date of first enrollment: 29/04/2023
• Target sample size: 23
• Study type: Interventional

Intervention(s)

Drug: Pembrolizumab
200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
Other Names:
Keytruda
MK-3475
Drug: Paclitaxel
80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
Drug: Carboplatin
Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
Drug: Olaparib
300 mg BID (twice daily) orally
Other Name: Lynparza
Procedure: Definitive Surgery
Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.

Outcome(s)

• Primary Outcome: Pathological Complete Response (pCR) Rate (ypT0/TisypN0) [ Time Frame: From 27 weeks up to 30 weeks ]

Secondary Outcome

1) Residual Cancer Burden 0/1 [ Time Frame: From 27 weeks up to 30 weeks ]
2) Pathological Complete Response (pCR) Rate (ypT0/is) [ Time Frame: From 27 weeks up to 30 weeks ]
3) Pathological Complete Response (pCR) Rate (ypT0/Tis ypN0) [ Time Frame: From 27 weeks Up to 30 weeks ]
4) Three-Year Overall Survival (3-year OS) [ Time Frame: Up to 3 years ]
5) Three-Year Distant Metastatic Free Survival (3-year DMFS) [ Time Frame: Up to 3 years ]
6) Three-Year Event Free Survival (3-year EFS) [ Time Frame: Up to 3 years ]
7) AEs/SAEs and treatment discontinuation due to AEs/SAEs [ Time Frame: Up to 3 years ]

Key inclusion & exclusion criteria

• Age minimum: > 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1)Male/female subjects who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of invasive breast cancer
2)Have histologically confirmed TNBC, as defined by the most recent ASCO/CAP guidelines.
3)Confirmed germline BRCA 1/2 mutated.
4)Have previously untreated locally advanced non-metastatic (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per AJCC for breast cancer staging criteria version 7 as assessed by the investigator based on radiological and/or clinical assessment:
T1c, N1-N2
T2, N0-N2
T3, N0-N2
T4a-d, N0-N2
5)It has been confirmed that there is no distant metastasis to each organ by the following tests. Chest: Contrast CT or FDG-PET/CT Abdominal: Contract CT* or FDG-PET/CT Bone: Bone scintigraphy or FDG-PET/CT Brain: In the case of no central nervous system symptoms, examination for brain metastasis is not required.
6)The subject (or legally acceptable representative if applicable) provides written informed consent for the trial.
7)Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
8)Have adequate organ function as defined in the protocol. Specimens must be collected within 14 days prior to the start of study treatment.

Exclude criteria

1) Subjects who has a positive urine pregnancy test within 72 hours prior to registration
2) Has diagnosed as inflammatory breast cancer.
3) Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor .
4) Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug.
5) Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
6) Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
7) Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
8) Has severe hypersensitivity (more than Grade 3) to pembrolizumab and investigational drugs used in this study and/or any of their excipients.
9) Has active autoimmune disease that has required systemic treatment in the past 2 years
10) Has a history of (non-infectious) pneumonitis/interstitial lung disease .
11) Has an active infection requiring systemic therapy.
12) Has a known history of Human Immunodeficiency Virus (HIV) infection.
13) Has a known history of Hepatitis B (defined as Hepatitis B surface antigen reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.
14) Has a known history of active TB (Bacillus Tuberculosis).
15) Has a history or current evidence of any condition, therapy, or laboratory abnormality.
16) Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
17) Is pregnant or breastfeeding, or expecting to conceive or father children.
18) Has had an allogenic tissue/solid organ transplant.
19) Has received pre-treatment with Olaparib or other PARP inhibitors.
20) Has significant cardiovascular disease
21) Has a resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions.
22) Subject has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
23) Subject received colony-stimulating factors within 28 days prior to the first dose of study intervention.
24) Subject is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
25) Is either unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption.
26) Is, in the judgement of the investigator, unlikely to comply with the study procedures, restrictions, and requirements of the study.
27) Is currently receiving either strong or moderate inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study.
28) Is currently receiving either strong or moderate inducers of CYP3A4 that cannot be discontinued for the duration of the study.

Related Information

• Primary Sponsor: Takahashi Yuko
• Source(s) of Monetary Support: Merck Sharp & Dohme LLC
• Secondary ID(s): NCT05485766